# Tony Brooks

> Tony Brooks is a seed investor at Genome British Columbia backing Health Care and Medical Device. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Genome British Columbia](https://shizune.co/investors/profile/genome-british-columbia)
- Total investments: 3
- Last investment: Feb 2023
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/tony-brooks-0903127/?originalSubdomain=ca

Tony Brooks is a seed investor at Genome British Columbia focused on Health Care and Medical Device. Tony Brooks is the CFO and VP Entrepreneurship & Commercialization at Genome British Columbia. Tony Brooks attended University of London.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Medical Device | 2 | 67% |
| Hardware | 1 | 33% |
| Electronics | 1 | 33% |
| Water Purification | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 67% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Arbutus Medical | Every hospital in the world is faced with a major challenge - the rising cost of heathcare - we want to do something about it. Arbutus Medical’s purpose is to develop a portfolio of “frugal innovation” devices that save costs for hospitals and improve access to orthopedic surgery for 5 million patients by 2030. Arbutus Medical's flagshipproduct is a radically affordable orthopaedic power tool system that is used in North American Trauma Centers, veterinary hospitals, military deployments, NGO missions, and hospitals in over 30 low- and middle-income countries worldwide. | $2.3M | Seed | Feb 13, 2023 |  |
| Sonic Incytes | Sonic Incytes is a medical device start-up company developing quantitative ultrasound for point-of-care diagnostic and procedure guidance. our mission to enable routine assessment and management of liver health, with diagnostic accuracy you can count on. | $2.5M | Seed | May 28, 2020 |  |
| Acuva Technologies | Acuva Technologies is developing ultraviolet light emitting diode (UV-LED) based drinking water purification systems targeting low to moderate volumes of water in various sizes. Acuva’s reactor is a compact, modular, and scalable system comprising UV LEDs, to provide a dose of UV radiation to water flowing through the device. The UV puriicationsystem obtains germicidal destruction of biological contaminants such as viruses and bacteria. | $1M | Series B | Sep 30, 2019 |  |

3 of 3 investments shown.

## Co-investors
- [Nimbus Synergies Inc.](https://shizune.co/investors/profile/discovery-park-technology-fund) — VC Fund, 1 deal together
- [E-Fund](https://shizune.co/investors/profile/e-fund) — VC Fund, 1 deal together
- [MEDTEQ+](https://shizune.co/investors/profile/medteq) — VC Fund, 1 deal together
- [ScaleGood Fund LP (powered by TELUS)](https://shizune.co/investors/profile/scalegood-fund) — VC Fund, 1 deal together
- [Small World Group](https://shizune.co/investors/profile/small-world-group) — VC Fund, 1 deal together
- [Sunhope Capital](https://shizune.co/investors/profile/sunhope-capital) — VC Fund, 1 deal together

## About Genome British Columbia

VC Fund · Vancouver, Canada

Genome BC, a non-profit research organization, leads genomics innovation on Canada’s West Coast and facilitates the integration of genomics into society. Their major investors are the Province of British Columbia and the Government of Canada through Genome Canada and Western Economic Diversification Canada. This funding is complemented bypartnerships with many national and international public and private funding organizations to drive BC’s bioeconomy.

3 contacts available at Genome British Columbia.

| Name | Title | Profile |
| --- | --- | --- |
| Tony Brooks | CFO& VP Entrepreneurship & Commercialization | https://shizune.co/investors/profile/tony-brooks-4e9b |
| Catalina Lopez-Correa | Chief Scientific Officer & Vice President Sectors | https://shizune.co/investors/profile/catalina-lopez-correa |
| Federica Di Palma | Chief Scientific Officer and Vice President Sectors | https://shizune.co/investors/profile/federica-di-palma |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Tony Brooks invest in?

Tony Brooks invests primarily in Health Care, Medical Device and Hardware startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tony Brooks last invest?

The most recent investment recorded for Tony Brooks closed in Feb 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co